Detection of circulating tumor cells and its correlation with clinical outcome in non-small cell lung cancer.

• DOI: 10.1200/jco.2014.32.15_suppl.e22020
• Publication Date: 2019-01-03T17:39:30Z
• Authors: Milena Tariki; Juliana Valim Romero; Emne Ali Abdallah; Luciana Menezes M...; Natalia Breve Min...; Jose Luiz Gaspari...; Vanessa Alves Silva; Marcello Ferretti...; Aldo A. Dettino; Augusto Akikubo R...; Ludmilla T. D. Ch...
• Keywords: Circulating tumor cell; ERCC1

e22020 Background: The presence of circulating tumor cells (CTCs) is a necessary process for cancer progression. In fact, its detection has surged as potential biomarker clinical response in treatment patients with non-small cell lung (NSCLC). This study analyzed level CTCs and outcome, well expression genes related to drug resistance. Methods: Consecutive single institution stage I-IV NSCLC were included. Isolation, counting characterization made by ISET (Isolation Size Epithelial Tumors; RareCell Diagnostics, Paris, France). Levels blood samples before systemic every two months thereafter. Serum levels correlated DFS. Expression ERCC1 was cisplatin-based treatment. Results: 45 included, 2.2% I (1 pt), II 11.1% III (5 pts 75.6% IV (34 pts). There 24 men (53.3%) 21 women (46.7%) the median age 65 years (34-81 years). no significant correlation between CTCs´ outcome. However, we observed non-significant better survival at first follow-up those found have less than 2 CTCs/mL (mean = 12.6 months) compared or more 5.8 months; p= 0.06). Four expressed their three them showed disease progression, sugesting that this protein be used biomarker. Conclusions: could predictor poor outcome NSCLC, seen previous studies. progression our analysis needs explored other prospective